9SO Stock Overview
Engages in the development and marketing of oncology drugs in Japan and other Asian countries. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Solasia Pharma K.K. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥0.23 |
| 52 Week High | JP¥0.38 |
| 52 Week Low | JP¥0.13 |
| Beta | 1.3 |
| 1 Month Change | -18.31% |
| 3 Month Change | -9.38% |
| 1 Year Change | -31.36% |
| 3 Year Change | -70.82% |
| 5 Year Change | -84.43% |
| Change since IPO | -90.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9SO | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -4.1% | -3.5% | -2.0% |
| 1Y | -31.4% | -14.7% | 6.9% |
Return vs Industry: 9SO underperformed the German Biotechs industry which returned -14.7% over the past year.
Return vs Market: 9SO underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| 9SO volatility | |
|---|---|
| 9SO Average Weekly Movement | 14.5% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 9SO's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 9SO's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 24 | Yoshihiro Arai | www.solasia.co.jp |
Solasia Pharma K.K. engages in the development and marketing of oncology drugs in Japan and other Asian countries. The company offers episil oral liquid for the protection and relief of oral pain associated with oral mucositis/stomatitis caused by chemotherapy and radiotherapy for cancer; Sancuso, a transdermal delivery system that delivers granisetron, an anti-emetic into the patient’s bloodstream for the treatment of chemotherapy induced nausea and vomiting; and Darvias injection, and antineoplastic agent/organic arsenic product indicated for relapsed or refractory peripheral T-cell lymphoma. It is also involved in the development of SP-04, a chemotherapy induced peripheral neuropathy which is in pre-clinical stage.
Solasia Pharma K.K. Fundamentals Summary
| 9SO fundamental statistics | |
|---|---|
| Market cap | €54.58m |
| Earnings (TTM) | -€7.43m |
| Revenue (TTM) | €586.92k |
88.5x
P/S Ratio-7.0x
P/E RatioIs 9SO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9SO income statement (TTM) | |
|---|---|
| Revenue | JP¥96.00m |
| Cost of Revenue | JP¥85.00m |
| Gross Profit | JP¥11.00m |
| Other Expenses | JP¥1.23b |
| Earnings | -JP¥1.21b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.58 |
| Gross Margin | 11.46% |
| Net Profit Margin | -1,265.63% |
| Debt/Equity Ratio | 0% |
How did 9SO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 23:01 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Solasia Pharma K.K. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nobumasa Morimoto | Mizuho Securities Co., Ltd. |
| Kyoichiro Shigemura | Nomura Securities Co. Ltd. |
| Dion Stéfan Büchner | Pathology Associates Co., Ltd. |